CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) insider Yuri Maricich bought 6,551 shares of the stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $1.65 per share, with a total value of $10,809.15. Following the completion of the acquisition, the insider directly owned 12,611 shares of the company’s stock, valued at approximately $20,808.15. The trade was a 108.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
CAMP4 Therapeutics Stock Down 5.8%
CAMP4 Therapeutics stock opened at $4.24 on Friday. The company has a market capitalization of $220.18 million, a P/E ratio of -1.80 and a beta of 0.22. The stock’s 50 day moving average is $4.02 and its 200 day moving average is $4.30. CAMP4 Therapeutics Corporation has a twelve month low of $1.32 and a twelve month high of $7.75.
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). The company had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. As a group, equities analysts expect that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on CAMP shares. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Rodman & Renshaw initiated coverage on shares of CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target on the stock. Zacks Research downgraded shares of CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Chardan Capital set a $6.50 target price on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.36.
Read Our Latest Report on CAMP
About CAMP4 Therapeutics
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Featured Articles
- Five stocks we like better than CAMP4 Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
